Evidence map›Paper›PMID 39358480›Full record

ReviewCell regeneration (London, England)2024

Targeting senescent cells in aging and COVID-19: from cellular mechanisms to therapeutic opportunities.

Yuan Yu, Kaixuan Lin, Haoyu Wu, Mingli Hu, Xuejie Yang, Jie Wang, Johannes Grillari, Jiekai Chen

Abstract readReview
In one paragraph

Review in Cell regeneration (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuan Yu *Center for Cell Lineage and Atlas, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangdong-Hong Kong Joint Laboratory for Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China.
Kaixuan Lin *Center for Cell Lineage and Atlas, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangdong-Hong Kong Joint Laboratory for Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China. lin_kaixuan@gibh.ac.cn.
Haoyu WuCenter for Cell Lineage and Atlas, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangdong-Hong Kong Joint Laboratory for Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China.
Mingli HuCenter for Cell Lineage and Atlas, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangdong-Hong Kong Joint Laboratory for Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China.
Xuejie YangCenter for Cell Lineage and Atlas, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangdong-Hong Kong Joint Laboratory for Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China.
Jie WangCenter for Cell Lineage and Atlas, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangdong-Hong Kong Joint Laboratory for Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China.
Johannes GrillariAustrian Cluster for Tissue Regeneration, Vienna, Austria.
Jiekai ChenCenter for Cell Lineage and Atlas, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangdong-Hong Kong Joint Laboratory for Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China. chen_jiekai@gibh.ac.cn.

Funding

Austrian Science Fund 'Herzfelder'sche Familienstiftung project P35268-BAustrian Science Fund the Austrian Science Fund (FWF)Basic and Applied Basic Research Foundation of Guangdong Province 2021A1515111044Bundesministerium für Bildung, Wissenschaft und Forschung BMBWFBundesministerium für Bildung, Wissenschaft und Forschung WTZ-OEAD grant (CN 04/2021)Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences Basic Research Project of Guangzhou Institutes of BiomedicineGuangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences Chinese Academy of Sciences (GIBHBRP23-02)Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences HealthGuangzhou Municipal Science and Technology Project 2024A04J4199Ministry of Science and Technology of the People's Republic of China National Key R&D Program of China (2021YFE0112900)National Natural Science Foundation of China 32000414Science and Technology Planning Project of Guangdong Province 2023B1212060050Science and Technology Planning Project of Guangdong Province 2023B1212120009
6 · The paper itself

Abstract

The COVID-19 pandemic has caused a global health crisis and significant social economic burden. While most individuals experience mild or non-specific symptoms, elderly individuals are at a higher risk of developing severe symptoms and life-threatening complications. Exploring the key factors associated with clinical severity highlights that key characteristics of aging, such as cellular senescence, immune dysregulation, metabolic alterations, and impaired regenerative potential, contribute to disruption of tissue homeostasis of the lung and worse clinical outcome. Senolytic and senomorphic drugs, which are anti-aging treatments designed to eliminate senescent cells or decrease the associated phenotypes, have shown promise in alleviating age-related dysfunctions and offer a novel approach to treating diseases that share certain aspects of underlying mechanisms with aging, including COVID-19. This review summarizes the current understanding of aging in COVID-19 progression, and highlights recent findings on anti-aging drugs that could be repurposed for COVID-19 treatment to complement existing therapies.

Indexed as

AgingAnti-aging TherapiesCellular SenescenceCOVID-19

Identifiers

PMID39358480
PMCPMC11447201

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.